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Pre-eclampsia is a pregnancy disease that complicates 2-5% of pregnancies worldwide (1). It 
is characterised by the development of hypertension and proteinuria after 20 weeks’ gestation 
(2). Pre-eclampsia is thought to occur secondary to abnormal placentation in early pregnancy 
(3) resulting from impaired placental trophoblast invasion and subsequent generation of an 
ischemic environment (4). Placental ischemia is proposed to increase placental oxidative 
stress leading to the shedding of syncytiotrophoblast debris into the maternal circulation 
where it initiates a systemic maternal inflammatory response and subsequent endothelial 
dysfunction (5).  
Oxidative stress is a cellular or physiological condition of elevated levels of reactive oxygen 
species (ROS) which damage cell structure and function. Antioxidant enzymes including 
superoxide dismutase (SOD) and glutathione peroxidase are components of the body’s 
mechanism for combating oxidative stress. SOD is a powerful antioxidant that catalyses the 
reaction between two identical molecules of superoxide radical into oxygen or hydrogen 
peroxide. There is significant evidence that oxidative stress plays a role in the 
pathophysiology of pre-eclampsia (6, 7). Normal pregnancy is associated with an increase in 
oxidative stress due to a rise in maternal metabolism and maternal blood flow in the placenta 
by 10–12 weeks’ gestation (8). However, in pregnancies complicated by pre-eclampsia there 
is an exaggerated oxidative stress phenotype with a correspondent deficient antioxidant 
response.  
Mitochondria are the dominant cellular source of ROS and there is strong evidence that 
mitochondrial ROS (mROS) play an important role in a variety of physiological processes 
including the regulation of cell differentiation, apoptosis, redox cell signalling and 
inflammation (9-11). Furthermore, our research has implicated mitochondrial dysfunction as 
a potential mediator of oxidative stress in pre-eclampsia (10). Cell-free DNA (cf-DNA) has 
been investigated as a universal diagnostic biomarker for a number of clinical applications, 
such as prenatal diagnosis and cancer monitoring (12, 13). Circulating cell free DNA is 
composed of both nuclear and mitochondrial DNA. Mitochondrial DNA (mtDNA) encodes 
for 37 genes programmed by the mitochondrial genome (14) and is often used as a biomarker 
of mitochondrial dysfunction. mtDNA are particularly vulnerable to oxidative damage due to 
its intimate location in  the electron transport chain (ETC) in the mitochondrial matrix and its 
lack of protective histones (15). More recently, there is emerging evidence suggesting that 
cell-free mtDNA (cf-mtDNA) is linked to disease progression such as, cardiovascular disease 
(16). Circulating DNA in maternal plasma is mostly of maternal origin (hematopoietic and 
stromal derived) depending on gestational week and maternal bodyweight. Approximately 5-
20% of the circulating DNA is derived from fetal/placental cells (17).  
Our research has previously shown an increase in mtDNA in plasma samples at time of 
disease (TOD) in women with pre-eclampsia (18). Hence the aim of this study was to 
characterise the role of mitochondrial dysfunction in women with pre-eclampsia compared to 
uncomplicated pregnancies by assessing levels of antioxidant enzyme superoxide dismutase 
and mtDNA at earlier time-points in pregnancy.  We also examined if lifestyle and dietary 
factors affected mtDNA levels in pregnancy. We hypothesised that mitochondrial 
dysfunction plays a role in the pathogenesis of pre-eclampsia. 
Methods:  
Study subjects 
Subjects were recruited from the Screening for Pregnancy Endpoints (SCOPE) study Ireland 
which is an international multicentre prospective cohort study of nulliparous singleton 
pregnancies aimed to develop a screening test to predict adverse pregnancy outcomes 
including pre-eclampsia, SGA infants and spontaneous pre-term birth (19, 20). The clinical 
research ethics committee, University College Cork, approved the collection and use of 
samples for research purposes. A nested case-control study within SCOPE Ireland was 
conducted which included all pre-eclampsia cases in SCOPE Ireland and matched controls 
with a case-to-control ratio of 1:2. Pre-eclampsia cases were defined as women with systolic 
blood pressure ≥ 140mm Hg and/or diastolic blood pressure ≥ 90 mm Hg on at least two 
occasions 4 hrs apart after 20 weeks’ gestation and with proteinuria (24 hour urinary protein 
≥ 300mg or urine dipstick protein ≥ +2). Randomly selected controls were taken from healthy 
pregnant women who had uncomplicated pregnancies which were defined as pregnancies not 
affected by pre-eclampsia, preterm birth or growth restriction and delivered at >37 weeks. All 
blood pressure readings were <140 and/or <90 mmHg prior to the onset of labour. These 
were matched with the cases for maternal age, body mass index (BMI) and gestational age.  
Both 15 and 20 week samples were taken from the SCOPE study from women who 
subsequently went onto develop pre-eclampsia (n=60) and controls (n=120). Samples were 
also taken from a subset of women (n=25) at the time of disease (TOD) with pre-eclampsia.  
Superoxide Dismutase enzyme activity 
Superoxide dismutase activity was quantified in citrate plasma samples using a superoxide 
dismutase assay kit (Cayman chemical) which was used as per manufacturer’s instructions. 
This assay utilizes tetrazolium salt for detection of superoxide radicals generated by xanthine 
oxidase and hypoxanthine. This assay measures a combination of activity from all three 
isoforms.  
Sample collection and DNA extractions 
Plasma samples were collected in BD Heparin Vacutainer tubes, placed on ice, and 
centrifuged at 2,400g for 10 minutes at 4˚C according to the standardised protocol. Plasma 
samples were stored at -80˚C until analysis. Samples were analysed in a blinded manner. 
Total DNA was extracted from 200µl of plasma from both controls and cases respectively 
with a QIAamp DNA mini kit (Qiagen). DNA was sonicated at 38 kHz ± 10% for 10 minutes 
to optimise DNA yield. 
mtDNA quantification 
Mitochondrial DNA was measured by real-time PCR using StepOne Plus Detection system 
using Taqman assays for mitochondrial DNA (hMitoF5, hMitoR5) (21). Absolute 
quantification of the concentration of mitochondrial DNA (mtDNA) was determined by 
standard curve analysis and presented as copies/ml (21, 22). 
Maternal lifestyle factors 
Women were asked at recruitment (15 ± 1 weeks of gestation) and at their second visit (20 ± 
1 weeks of gestation) how many times each week did they carry out exercise that did not 
result in heavy breathing, which was the SCOPE definition of moderate-intensity exercise. 
The response was categorised as never, 1-3 times a week and daily. Similarly, the 
questionnaire administered at both time points asked women to report the frequency in which 
the consumed fruit and leafy vegetables. Scoring was similar to exercise, where the response 
was categorised as never, less than five pieces a week, and daily. Multivitamins were 
categorised into never, less than daily and daily.  
Statistical analysis  
Analysis was performed using GraphPad Prism and SPSS version 22 (SPSS Inc. Chicago, 
Illinois). Data were presented using median (±Interquartile range [IQR]) and comparisons of 
data between cases and controls were performed using a non-parametric Mann Whitney U 
test or Wilcoxon signed rank test as appropriate when data was not normally distributed. Data 
that was normally distributed were represented as mean (±SEM) and comparisons of data 
between cases and controls were performed using an unpaired t-test. P values <0.05 were 
considered as statistically significant. Chi-squared test and the odds ratio (OR) was used to 
compare categorical variables.  
Results:  
Patient characteristics  
There were 1,774 participants in the SCOPE Ireland study. 68 (3.8%) women were diagnosed 
with pre-eclampsia and 60 were included in the nested case-control study with 120 
participants selected as controls. The 60 women with pre-eclampsia were composed of 39 
women who developed term pre-eclampsia and 21 preterm pre-eclampsia cases. As all cases 
and controls were matched nulliparous women, there was no significant differences observed 
between case-controls studies for maternal age, BMI, and gestational age at delivery. There 
was a significant difference in mean arterial blood pressure (MAP) in controls versus cases at 
both 15 and 20 weeks’ gestation respectively (median [IQR]; 78.0 mmHg [73.33-83.33], 
n=120, vs median [IQR]; 82.0 mmHg [75.0- 87.66], n=60, p= 0.0015 and media [IQR] 80.41 
mmHg [75.3333- 85.0], n=120, vs median [IQR]; 83.5 mmHg [77.5- 89.83] n=60, p= 0.02). 
There was a significant difference in birthweight in controls compared to cases (3608.93 g ± 
411.90 vs 2990.86 g ± 759.24; n=120, n=60; p<0.0001). (Table 1). 
Evidence of altered plasma SOD activity before pre-eclampsia. 
There was a statistically significant reduction in antioxidant SOD activity at 15 weeks’ 
gestation between controls and cases (1.94 ng/ml ± 0.06 vs 1.69 ng/ml ± 0.06; n=60, n=119; 
p< 0.01; 95% CI; 0.04 to 0.45; Figure 1A). There was no significant difference in SOD 
activity at 20 weeks’ gestation between controls and cases, (0.82 ng/ml ± 0.02 vs 0.77 ng/ml 
± 0.03; n=119 p=0.21; 95% CI; -0.02 to 0.12; Figure 1B). 
Increased ΔmtDNA levels was evident between 15 and 20 weeks’ before pre-eclampsia. 
There was no significant difference in the amount of total DNA between controls and cases at 
both 15 and 20 weeks’ gestation (15 weeks: 7.06 ng/ml ± 4.08 vs 7.70 ng/ml ± 5.43 , n =60 
n=120, p=0.38; 20 weeks 6.71 ± 3.26 vs 7.15 ± 3.44 , n= 60 n=120, p=0.40; Figure 2A). 
There was no significant difference in mtDNA at 15 weeks’ gestation between controls and 
cases (median [IQR]: 2832.96 copies/ml [1711.17-5002.82] vs 2337.32 copies/ml [1357.11-
5328.35], n=58-117; p< 0.3381, Figure 2B). Similarly, there was no significant difference in 
mtDNA at 20 weeks’ gestation between controls and cases and (median [IQR]:  2885.57 
copies/ml [1914.54-4834.12] vs 3307.7 copies/ml [1544.49-7396.92], n=58-117; p<0.7873, 
Figure 2C). As pregnancy progressed the amount of mtDNA significantly increased in pre-
eclampsia and healthy pregnancies (median [IQR]: 2337.32 copies/ml [1357.11-5328.35], 
3307.7 copies/ml [1544.49-7396.92] and 6449.8 copies/ml [477.54-11145.9] n=58 and 
n=22.p< 0.0001, and median [IQR]: 2855.41 copies/ml [1740.19-5322.08], 2900.95 
copies/ml [1958.36-5055.16], 5983.88 copies/ml [3209.67-16901.5] n-117 and n=23. 
P=0.009, Figure 2D) at 15 weeks’, 20 weeks’ and TOD respectively. 
However the mean difference in  mtDNA between 15 weeks’ and 20 weeks’ gestation was 
significantly higher in cases compared with controls (2236 ± 796.0 copies/ml vs -555.3 ± 
599.3 copies/ml mtDNA concentration in plasma, p=0.0065; Figure 2E). 
Lifestyle and nutritional factors; effect of these factors on mtDNA 
Moderate exercise had no significant impact on the amount of mtDNA in controls vs cases at 
15 or 20 weeks’ gestation OR 1.00; [CI 1.00-1.00 vs 1.00 CI [1.00-1.00] respectively (Table 
2A). When assessing dietary factors such as leafy vegetable intake, fruit intake and 
multivitamin consumption, similarly there was no effect on the amount of mtDNA at 15 or 20 
weeks’ gestation in controls vs cases (Table 3A, 3B, 3C).   
Discussion 
Mitochondrial dysfunction is a pathogenic mediator of oxidative stress in pre-eclampsia with 
elevated mitochondrial lipid peroxidation and increased vulnerability to oxidation evident in 
placental mitochondria in pregnancies complicated by pre-eclampsia (23). In this present 
study we showed a significant reduction in antioxidant SOD activity at 15 weeks’ gestation 
and an increase in the mean difference in mtDNA (between 15 and 20 weeks’ gestation) in 
cases compared to controls.  
Oxidative stress results from an imbalance in the production of ROS and the responsive 
antioxidant levels. There is a vast amount of evidence for antioxidant decline and elevation of 
ROS in pre-eclampsia (7, 24). SOD is the first barrier and antioxidant defence against ROS 
and its activity is increased in the placenta of a normal pregnancy (25), while SOD activity in 
placental tissue from women with pre-eclampsia is decreased (26). In our study, we showed 
lower levels of SOD activity at 15 weeks’ gestation in cases compared to controls. This 
correlates with previous work which showed lower levels of SOD at both 10-14 and 20-24 
weeks’ gestation respectively in pre-eclampsia (27). Similarly, the levels of maternal 
erythrocyte SOD were also lower in the second half of pregnancy in pre-eclampsia when 
compared with normotensive pregnancies (7).  
Mitochondrial DNA is correlated with the number and size of the mitochondria (28), 
furthermore mtDNA are particularly susceptible to oxidative damage. While the origin of cf-
mtDNA is difficult to phenotype, the quantitative assessment of cf-mtDNA may permit the 
evaluation of mitochondrial dysfunction in pre-eclampsia. There have been a number of 
studies that suggest mitochondrial abundance may be associated with placental insufficiency 
and pre-eclampsia (29-32). Our research previously showed evidence of increased mtDNA at 
time of disease in women with pre-eclampsia, furthermore, we provided additional evidence 
of mitochondrial dysfunction by demonstrating increased mitochondrial-specific ROS and  
reduced oxygen consumption (18). In this current study, while there was no significant 
difference in mtDNA copy number at both 15 and 20 weeks’ gestation respectively in cases 
compared with controls, we reported a significant increase in the mean difference in mtDNA 
copy number between 15 and 20 weeks’ gestation in cases compared with controls.  
Given the critical role of SOD antioxidants in mediating oxidative damage provoked by 
exaggerated superoxide generation, the compromised antioxidant defence evident at 15 
weeks’ gestation in cases in our study group may be partly responsible for increased 
vulnerability of mtDNA  damage as evident by the increase in mean difference in mtDNA 
between 15-20 weeks’ gestation. Previous work in retinal endothelial cells overexpressing 
SOD2 (33) and in SOD2-depleted chrondrocytes (34) has established an essential protective 
role for this enzyme in preventing mtDNA damage. Furthermore, we showed that mtDNA 
copy number increases as pregnancy progresses in women with pre-eclampsia and we 
hypothesise that the initial insult to mitochondrial antioxidant function seen early in 
pregnancy (15 weeks) could be exacerbated later in pregnancy resulting in a more significant 
increase in mtDNA copy number in pre-eclampsia as we previously described.  
The strength of our data compared to previous work in this area is attributable to the 
longitudinal examination of mtDNA through gestation, whereas previous studies have 
focused on mtDNA quantitation in the third trimester of pregnancy. This work correlates with 
previous studies, where mtDNA copy number was assessed in a case-control study and 
reported that the odds of pre-eclampsia were positively associated with increased maternal 
blood mtDNA copy number (31). These findings strongly suggest that altered mitochondrial 
function is evident very early in the development of pre-eclampsia. This study was performed 
in the Irish SCOPE cohort and while we provide evidence of mitochondrial dysfunction in 
pre-eclampsia, further larger studies in different populations are warranted.  
Lifestyle interventions such as healthy diet (fruit and vegetable consumption) and exercise 
have been examined in mitochondrial diseases (35, 36).  In recent years, exercise has been 
intensively researched in relation to reducing risk of pre-eclampsia (37, 38). The next step in 
this study was to assess whether lifestyle and nutritional factors had an effect on the amount 
of mtDNA in controls and cases.  However, we showed that exercise had no significant 
difference on mtDNA copy number during pregnancy in controls or cases. Similarly, a 
previous study assessed exercise and mtDNA copy number in controls and pre-eclampsia 
cases and showed no association between exercise and mtDNA copy number (31).  
Diet has been suggested to play a potential role in the management of pre-eclampsia (39). In 
our study we found no association between fruit and vegetable intake on mtDNA copy 
number in control and cases. Similarly, Clausen et al, showed no association between 
pregnancies affected by pre-eclampsia and healthy pregnancies when investigating meat, fish, 
vegetables and fruit intake (40). Finally we investigated multivitamin intake and its 
association with mtDNA copy number in control and cases and found no association. Both 
Vitamin C and E have been extensively studied as antioxidant therapeutic options in pre-
eclampsia (41, 42), however the results were largely disappointing. This may have occurred 
as these exogenous antioxidant vitamins do not penetrate the intracellular source of ROS, the 
mitochondria, and are sequestered in the cytosol. Therefore, we propose a mitochondrial-
targeted antioxidant may represent a more promising clinically effective treatment strategy 
for pre-eclampsia.  
Conclusion 
In this study, we provide evidence that in early gestation there is a significant reduction in 
mitochondrial antioxidant SOD activity in women who developed pre-eclampsia. 
Furthermore, there is a significant increase in ΔmtDNA levels between 15 and 20 weeks’ in 
women who subsequently went on to develop pre-eclampsia. Our findings support a 
pathogenic role for mitochondrial dysfunction in the pathophysiology of pre-eclampsia. 
Finally, we found no effect of either lifestyle or dietary factors in mediating mitochondrial 
dysfunction in this study cohort, highlighting the potential need for the development for 
mitochondrial targeted antioxidants as potential therapeutic targets to treat pre-eclampsia.  
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Mean Maternal age, 
years 31 29 29 
Mean BMI 25 26 25 
    
Maternal    
Mean Arterial Blood 




88.0] 78 [73.33-83.33] 
    
Mean Arterial Blood 
Pressure at 20 weeks 
81.33 [77.66-
89.66] 83 [76.08-87.0] 
80.41 [75.33-
85.0] 
    
Fetal     
Mean Birth weight, g 2104 3300 3608 
Mean gestational age at 
delivery  34 38 40 
Perinatal death 1 1 0 
Data are presented as mean or Median [IQR]. Mean Arterial blood pressure was calculated as MAP = 
(2 x diastolic) + systolic/3 and  
 
 
Table 2: The effect of lifestyle factors (Exercise) on mtDNA in cases compared to controls at 
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Table 3 (A): The effect of dietary factors (Fruit intake) on mtDNA in cases compared to 








intake   
N=58 Case (mtDNA copy 
number/ml) 
N=117 Control (mtDNA 
copy number/ml) 
OR  (95% 
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Never 0  1 6802.61 1.00 1.00-
1.00 













Table 3 (B): The effect of dietary factors (leafy vegetable intake) on mtDNA in cases 









N=58 Case (mtDNA 
copy number/ml) 
N=117 Control (mtDNA 
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OR  (95% 
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Never 1 4198.29 (4198.29-
4198.29) 
3 1846.20 (1108.22-) 1.00 1.00-
1.00 















Table 3 (C): The effect of dietary factors (Multivitamin intake) on mtDNA in cases compared 





intake   
N=58 Case (mtDNA 
copy number/ml) 
N=117 Control (mtDNA 
(copy number/ml 
OR  (95% 
CI) 










Less than daily 0  7 3518.35 (1856.43-
4315.26) 
  

















Figure 1: A) SOD activity (U/ml) was significantly reduced at 15 weeks in cases compared to 
healthy controls (P<0.01). B) SOD activity (U/ml) at 20 weeks was reduced in cases 
compared to healthy controls. Data are expressed as mean ± SEM. 
Figure 2: A) Total DNA in maternal plasma in controls and cases showed no significant 
difference. B) mtDNA at 15 weeks showed no significant difference in controls when 
compared to cases C) mtDNA at 20 weeks was higher in controls compared to cases but not 
statistically significant D) Mitochondrial dysfunction is significantly increased as gestation 
progresses in pre-eclampsia and uncomplicated pregnancies (p<0.001 and p=0.0009) 
respectively.●=cases, ■=control. Data represented as the median; [IQR]. E) Significant 
increase in the mean difference in mtDNA concentration between 15 and 20 weeks gestation 
in cases compared to controls (P<0.01). Data represented as the mean; [SEM]. 
 
 
 
 
